Impact of Saccharomyces cerevisiae and Sulfaclozine on lipid profile of broilers chicken

Abstract

The poultry industry plays a major role in satisfying the nation's meat consumption needs. Broiler meat is readily available and reasonably priced. This study sought to determine how Saccharomyces cerevisiae, when co-administered with a sulfonamide derivative (sulfaclozine 30%), affects broiler lipid profiles and protects against deleterious effects. In this experiment, 100 broilers that were 21 days old were split up into five groups. The first group served as a control, and the second group received sulfaclozine (30 mg/kg). Sulfaclozine 70 mg/kg b.w.t. was administered to the third group, followed by 1.5 gm/L of Saccharomyces cerevisiae mixed with 30 mg/kg b.w.t. for the fourth group and 1.5 gm/L of Saccharomyces cerevisiae combined with 70 mg/kg b.w.t. for the fifth group for 20 consecutive days. Lipid profiles were determined at 26, 31, 36, and 41 days of age, respectively. In the fourth and fifth groups treated with Saccharomyces cerevisiae and different doses of sulfaclozine, the lipid profile decreased, except for high-density lipoprotein (HDL). In the second and third groups treated with sulfaclozine, the lipid profile significantly increased, whereas HDL levels decreased. Ultimately, it was determined that Saccharomyces cerevisiae is a secure and efficient method for assessing the adverse effects of sulfonamides.